Journal Mobile Options
Table of Contents
Vol. 28, No. 5, 1998
Issue release date: September–October 1998 (July 1999)
Section title: Original Paper
Haemostasis 1998;28:236–243
(DOI:10.1159/000022437)

Secondary Prevention of Venous Thromboembolism: A Role for Low-Molecular-Weight Heparin

Monreal M. · Roncales F.J. · Ruiz J. · Muchart J. · Fraile M. · Costa J. · Hernandez J.A.
aServicio de Medicina Interna, b Servicio de Hematología, c Servicio de Neumología, dServicio de Radiodiagnóstico, e Servicio de Medicina Nuclear y f Servicio de Farmacología Clínica, Hospital Universitari Germans Trias i Pujol, Badalona, España

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 7/7/1999

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: http://www.karger.com/PHT

Abstract

Background: After a short initial course of heparin therapy, patients with venous thrombo-embolism (VTE) require continuing anticoagulant therapy for several months after hospital discharge. At present, two small-scale studies have compared the efficacy and safety of low-molecular-weight heparin (LMWH) with warfarin in the secondary prevention of VTE. Patients and Methods: We studied 654 consecutive patients, 202 with pulmonary embolism (PE) and 452 patients with deep vein thrombosis (DVT) of the lower limbs. 220/654 patients (34%) were considered to have some contraindications to coumarin, and were discharged on LMWH (dalteparin, Fragmin®, 10,000 IU s.c. once daily). The remaining 434/654 patients were asked to choose between either coumarin or LMWH: 190 patients preferred LMWH and 244 coumarin. Patients were followed up for a 3-month (DVT patients) or 6-month (PE patients) period. Results: 14/654 patients (2%) developed recurrent VTE while on anticoagulant therapy. One in every three recurrent episodes was PE (which was fatal in 2/5 patients), and half of the recurrent DVT were located in the contralateral leg. We failed to find any differences between patients receiving LMWH and those on coumarin therapy, but recurrences were more common in patients with cancer (hazard ratio: 17.15; 95% CI: 4.0–73.5; p < 0.001). 21 patients (3.3%) bled (major bleeding 5 patients; minor bleeding 16). Bleeding was more common in patients on coumarin therapy (hazard ratio: 3.14; 95% CI: 1.20–8.22; p = 0.02). Conclusions: Long-term LMWH therapy proved to be both effective and safe in the long-term treatment of VTE. Thus, we suggest long-term LMWH therapy should be considered for patients with contraindications to coumarin, or those with difficulties in coming to laboratory control.


  

Author Contacts

Prof. Manuel Monreal
Servicio de Medicina Interna
Hospital Universitari Germans Trias i Pujol
E–08916 Badalona (Spain)
Fax +34 93 3952229, E-Mail mmonreal@ns.hugtip.scs.es

  

Article Information

Received: Received: March 27, 1998
Accepted in revised form: February 1, 1999
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 4, Number of References : 19

  

Publication Details

Haemostasis (International Journal on Haemostasis and Thrombosis Research)
Official Journal of the ‘Mediterranean League against Thromboembolic Diseases’

Vol. 28, No. 5, Year 1998 (Cover Date: September-October 1998 (Released July 1999))

Journal Editor: H.C. Hemker, Maastricht; V.V. Kakkar, London
ISSN: 0301–0147 (print), 1423–0038 (Online)

For additional information: http://www.karger.com/journals/hae


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 7/7/1999

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: http://www.karger.com/PHT


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.